☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tumors
Chi-Med Initiates Rolling Submission of NDA to the US FDA of Surufatinib to Treat Advanced Neuroendocrine Tumors
December 30, 2020
Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020
September 17, 2020
Roche's Polatuzumab Vedotin as Combination Therapy & Entrectinib Receives FDA's Priority Review for r/r Diffuse DLBCL & NT...
February 19, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.